Literature DB >> 32016842

Evidence of the involvement of spinal αB-crystallin in the maintenance of bone cancer pain in rats.

Li-Hua Hang1, Hao-Ming Chen2, Jian-Mang Yu2, Ying Xu3, Shu-Na Li3.   

Abstract

BACKGROUND: αB-crystallin (CRYAB) is a small heat shock protein that is able to inhibit neuroinflammatory responses under various pathological conditions. Some studies have proven that neuroinflammatory mechanisms play important roles in bone cancer pain (BCP). However, whether CRYAB participates in the maintenance of BCP has not yet been examined.
METHODS: Walker256 tumour cells were inoculated into the tibia to induce a rat model of BCP. Von Frey hairs were used to measure mechanical allodynia. Immunohistochemistry and western blotting were used to examine the expression level of CRYAB in the spinal dorsal horn.
RESULTS: The gradual development of mechanical allodynia was induced by the injection of Walker256 cells into the tibia. The downregulation of spinal CRYAB expression was found in BCP rats. The intrathecal administration of CRYAB (from days 9 to 15 post-inoculation) dose-dependently alleviated mechanical allodynia in BCP rats. Additionally, there were concomitant increases in spinal CRYAB expression and decreases in TNF-α expression.
CONCLUSIONS: Spinal CRYAB may participate in the maintenance of BCP in rats. The findings will help to identify new drugs for the management of BCP.

Entities:  

Keywords:  Bone cancer pain; Mechanism; Spinal cord; αB-Crystallin

Mesh:

Substances:

Year:  2020        PMID: 32016842     DOI: 10.1007/s43440-019-00052-7

Source DB:  PubMed          Journal:  Pharmacol Rep        ISSN: 1734-1140            Impact factor:   3.024


  2 in total

Review 1.  Advances in cancer pain from bone metastasis.

Authors:  Xiao-Cui Zhu; Jia-Li Zhang; Chen-Tao Ge; Yuan-Yang Yu; Pan Wang; Ti-Fei Yuan; Cai-Yun Fu
Journal:  Drug Des Devel Ther       Date:  2015-08-18       Impact factor: 4.162

2.  Sustained relief of trigeminal neuropathic pain by a blood-brain barrier penetrable PPAR gamma agonist.

Authors:  Morgan Zhang; Min Hu; Marena A Montera; Karin N Westlund
Journal:  Mol Pain       Date:  2019 Jan-Dec       Impact factor: 3.395

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.